News & Views

Telix Reports Third Quarter 2022 Financial Results

ASX, News,

Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September...

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

ASX, Clinical, News,

Telix today announces preliminary data from two separate investigator-initiated studies of TLX250-CDx (89Zr-DFO-girentuximab) in triple negative breast cancer (TNBC) and non-muscle-invasive bladder cancer (NMIBC), part of a comprehensive series of...

Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market

ASX, News,

Telix Quarterly Results and Investor Call / Webcast Notification

ASX, News,

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

ASX, News,

Health Canada Approves Illuccix® for Prostate Cancer Imaging

ASX, News,

Telix announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prostate cancer and localizing...

First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent

ASX, News,

Telix today announces the first commercial dose in New Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11...

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

ASX, Clinical, News,

First Patient in Australia Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent 

ASX, News,

Telix today announces the first commercial dose in Australia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11...